89bio Inc. (ETNB)
5.89
-0.16 (-2.64%)
At close: Apr 16, 2025, 3:59 PM
5.90
0.14%
After-hours: Apr 16, 2025, 05:00 PM EDT
-2.64% (1D)
| Bid | 5.84 |
| Market Cap | 860.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -367.08M |
| EPS (ttm) | -3.51 |
| PE Ratio (ttm) | -1.68 |
| Forward PE | -2.91 |
| Analyst | Buy |
| Ask | 5.94 |
| Volume | 1,105,765 |
| Avg. Volume (20D) | 2,702,495 |
| Open | 6.07 |
| Previous Close | 6.05 |
| Day's Range | 5.68 - 6.07 |
| 52-Week Range | 4.16 - 11.84 |
| Beta | 1.29 |
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorpor...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2019
Employees 93
Stock Exchange NASDAQ
Ticker Symbol ETNB
Website https://www.89bio.com
Analyst Forecast
According to 10 analyst ratings, the average rating for ETNB stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 391.94% from the latest price.
Stock Forecasts2 months ago
+15.72%
89bio shares are trading higher after Wolfe Resear...
Unlock content with
Pro Subscription
2 months ago
+26.23%
89bio shares are trading lower after the company announced it proposed a $250 million public offering of common stock and pre-funded warrants.
1 month ago · https://thefly.com
89bio price target lowered by $8 at H.C. Wainwright, here's why13 Nov 29 Jan
2 months ago · seekingalpha.com
89bio's Pegozafermin Is Now Gaining Momentum89bio's Pegozafermin Is Now Gaining Momentum
